Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?

被引:6
作者
Feng, Bo [1 ]
Yang, Rui-Feng [1 ]
Jiang, Han-Ji [1 ]
Xie, Yan-Di [1 ]
Zhang, Hai-Ying [1 ]
Jin, Qian [1 ]
Cong, Xu [1 ]
Wei, Lai [2 ]
机构
[1] Peking Univ, Peoples Hosp, Hepatol Inst, Beijing Key Lab Hepatitis C & Immunotherapy Liver, 11 Xizhimen South St, Beijing 100044, Peoples R China
[2] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Inst Precis Med, 168 Litang Rd, Beijing 102218, Peoples R China
关键词
Hepatitis C; HCV core antigen; HCV RNA; Diagnosis; Treatment; HCV RNA; MANAGEMENT; INFECTION;
D O I
10.1007/s10238-019-00588-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Value of hepatitis C virus (HCV) core antigen (cAg) test has been controversy in patients with low HCV loads for its lower sensitivity. We assessed correlation between HCV-cAg and HCV RNA in serum samples with low viral loads and analyzed the performance of HCV-cAg assay in determining diagnosis and treatment outcomes in chronic hepatitis C patients. Both HCV RNA and HCV-cAg were detected for 2298 serum samples. Correlation analysis was performed between the two tests. Receiver operating characteristics (ROC) curve was used to assess value of HCV-cAg test in determining diagnosis and response outcomes at the different HCV RNA thresholds. The two tests were correlated very well, and moreover, correlation in the low viral load group was higher than that in the high viral load group (r value: 0.901 and 0.517). Positive agreement of HCV-cAg >= 3 fmol/L was as high as 97.0% for HCV RNA >= 1000 IU/mL, and its negative agreement for HCV RNA < 15 IU/mL was up to 98.9% in all samples. Area under ROCs ranged from 0.939 to 0.992, regardless of HCV RNA thresholds. When lower limit of detection of HCV RNA was 15, 100 or 1000 IU/mL, positive predictive value of HCV-cAg was 96.8%, 98.8% or 92.4%, and its negative predictive value was 87.0%, 89.9% or 98.3%, respectively, on the basis of different cutoff values. High-sensitivity HCV-cAg detection may likely replace HCV RNA to confirm the existence of HCV and to guide the treatment of chronic HCV infection.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 25 条
[1]   Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals [J].
Alados Arboledas, Juan Carlos ;
Pavon Guerrero, Inmaculada ;
Blanco Rodriguez, Maria Jose ;
Torres Martos, Eva ;
Belen Perez, Ana ;
Cepero Leon, Cristina ;
Sierra Sanchez, Jesus F. ;
Lopez Prieto, Maria Dolores ;
Chueca Porcuna, Natalia ;
Ocete Mochon, Maria Dolores ;
Macias, Juan ;
de la Iglesia Salgado, Alberto ;
Rodriguez Granger, Javier ;
Delgado Fernandez, Marcial ;
Guerrero Lozano, Inmaculada ;
Reigadas Ramirez, Elena ;
Rivero, Antonio ;
Lozano Dominguez, Maria del Carmen ;
Viciana, Isabel ;
Galan Montemayor, Juan Carlos ;
Garcia Garcia, Federico .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 89 (01) :29-34
[2]   Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection [J].
Cetiner, Salih ;
Duran, Alev Cetin ;
Kibar, Filiz ;
Yaman, Akgun .
TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (03) :362-366
[3]   Hepatitis C core antigen highly correlated to HCV RNA [J].
Chang, Christine ;
Hung, Chao-Hung ;
Wang, Jing-Houng ;
Lu, Sheng-Nan .
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (12) :684-688
[4]   Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus [J].
Chung, Raymond T. ;
Davis, Gary L. ;
Jensen, Donald M. ;
Masur, Henry ;
Saag, Michael S. ;
Thomas, David L. ;
Aronsohn, Andrew I. ;
Charlton, Michael R. ;
Feld, Jordan J. ;
Fontana, Robert J. ;
Ghany, Marc G. ;
Godofsky, Eliot W. ;
Graham, Camilla S. ;
Kim, Arthur Y. ;
Kiser, Jennifer J. ;
Kottilil, Shyam ;
Marks, Kristen M. ;
Martin, Paul ;
Mitruka, Kiren ;
Morgan, Timothy R. ;
Naggie, Susanna ;
Raymond, Daniel ;
Reau, Nancy S. ;
Schooley, Robert T. ;
Sherman, Kenneth E. ;
Sulkowski, Mark S. ;
Vargas, Hugo E. ;
Ward, John W. ;
Wyles, David L. .
HEPATOLOGY, 2015, 62 (03) :932-954
[5]   EASL Recommendations on Treatment of Hepatitis C 2018 [J].
Pawlotsky J.-M. ;
Negro F. ;
Aghemo A. ;
Berenguer M. ;
Dalgard O. ;
Dusheiko G. ;
Marra F. ;
Puoti M. ;
Wedemeyer H. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511
[6]   Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients [J].
Feng, Bo ;
Yang, Rui-Feng ;
Zhang, Hai-Ying ;
Luo, Bi-Fen ;
Kong, Fan-Yun ;
Rao, Hui-Ying ;
Jin, Qian ;
Cong, Xu ;
Wei, Lai .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2015, 19 (04) :390-398
[7]   Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection A Systematic Review and Meta-analysis [J].
Freiman, J. Morgan ;
Tran, Trang M. ;
Schumacher, Samuel G. ;
White, Laura F. ;
Ongarello, Stefano ;
Cohn, Jennifer ;
Easterbrook, Philippa J. ;
Linas, Benjamin P. ;
Denkinger, Claudia M. .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (05) :345-+
[8]   Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen [J].
Ghanbari, Kazhal ;
Roushani, Mahmoud ;
Azadbakht, Azadeh .
ANALYTICAL BIOCHEMISTRY, 2017, 534 :64-69
[9]   Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients [J].
Jiang, Han-ji ;
Wang, Xiao-xiao ;
Luo, Bi-fen ;
Cong, Xu ;
Jin, Qian ;
Qin, Hong ;
Zhang, Hai-ying ;
Kong, Xiang-sha ;
Wei, Lai ;
Feng, Bo .
CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (03) :299-308
[10]   Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting [J].
Juelicher, Paul ;
Galli, Claudio .
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) :1-10